LEUVEN, Belgium, September 19 ThromboGenics NV(Euronext Brussels: THR), a biotechnology company focused on innovativetreatments for eye disease and cancer announces today its promotion to theBelgian Midcap index (Bel Mid Index or BELMID). After a quarterly review ofBelgian indices by Euronext Brussels, ThromboGenics will enter the Bel MidIndex from October 1, 2008.
The elevation of ThromboGenics to the Bel Mid Index reflects thesignificant progress the Company has made since its IPO in 2006. TheCompany's lead product, Microplasmin for back of the eye disease has advancedconsiderably with Phase III trials expected to begin in early 2009.Furthermore, the Company has recently signed a strategic alliance with Rochefor its novel anti-cancer antibody for up to EUR 500 million. ThromboGenicshas also continued to build and diversify its shareholder base, which iscomprised of both domestic and international investors.
Chris Buyse, Chief Financial Officer of ThromboGenics, commenting ontoday's announcement said: "We are very pleased to have been promoted to theBel Mid Index. ThromboGenics has undergone a marked progression since its IPOand in recent months has underlined its position as one of the leadingBelgian biotechnology companies. Our inclusion in this index will give usgreater exposure and access to a wider range of potential investors, whichwill be of value as we continue to execute our growth strategy."
ThromboGenics is a biotechnology company focused on discovery anddevelopment of biopharmaceuticals for the treatment of eye disease andcancer. The Company has several programs in Phase II clinical developmentincluding microplasmin, which is being evaluated as a treatment forvitreoretinal disorders and as a thrombolytic agent for vascular occlusivediseases. ThromboGenics is also developing novel antibody therapeutics incollaboration with BioInvent International; these include TB-402 (Anti-FactorVIII), scheduled to enter Phase II clinical development by the end of 2008,and TB-403 (Anti-PlGF). ThromboGenics and its development partner BioInvent,have recently signed a license agreement with Roche for TB-403 worth up toEUR500 million plus royalties. A Phase Ib clinical trial with TB-403 hasrecently begun in patients with late stage cancer.
ThromboGenics has built strong links with the University of Leuven andthe Flanders Institute for Biotechnology (VIB) and has exclusive rights tocertain therapeutics developed at these institutions. ThromboGenics isheadquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland andNew York, U.S. The Company is listed on Eurolist by Euronext Brussels underthe symbol THR. More information is available at http://www.thrombogenics.com.
Important information about forward-looking statements
Certain statements in this press release may be considered"forward-looking". Such forward-looking statements are based on currentexpectations, and, accordingly, entail and are influenced by various risksand uncertainties. The Company therefore cannot provide any assurance thatsuch forward-looking statements will materialize and does not assume anobligation to update or revise any forward-looking statement, whether as aresult of new information, future events or any other reason. Additionalinformation concerning risks and uncertainties affecting the business andother factors that could cause actual results to differ materially from anyforward-looking statement is contained in the Company's Annual Report.For further information please contact: ThromboGenics Chris Buyse, CFO Tel : +32-16-75-13-10, email@example.com ; Patrik De Haes, COO Tel : +32-16-75-13-10, firstname.lastname@example.org ; Desire Collen, Chairman